CCR5 inhibitors: up and coming new agents.
A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamentarium this year.
O'Neal
Reilly
R
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009154:Mutation; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D019713:Receptors, CCR5 / Q000235:genetics; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; C486781:vicriviroc